EXELIXIS, INC.

EXEL is the ticker symbol for EXELIXIS, INC., a publicly traded US company.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Key metrics include a return on equity of 10.9%, a debt-to-equity ratio of 0.34.

The company reports trailing twelve-month revenue of $231.09M and net income of $210.47M.

FINOTAUR aggregates real-time and fundamental data on EXEL to help traders and investors make informed decisions. Track EXEL in your trading journal alongside other positions for a unified view of your portfolio.